Indacaterol maleate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319521

CAS#: 753498-25-8 (malate)

Description: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved in 2009. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.

Chemical Structure

img
Indacaterol maleate
CAS# 753498-25-8 (malate)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 319521
Name: Indacaterol maleate
CAS#: 753498-25-8 (malate)
Chemical Formula: C28H32N2O7
Exact Mass: 0.00
Molecular Weight: 508.571
Elemental Analysis: C, 66.13; H, 6.34; N, 5.51; O, 22.02

Price and Availability

Size Price Availability Quantity
100mg USD 150
200mg USD 250
500mg USD 550 2 Weeks
1g USD 950 2 Weeks
2g USD 1650 2 Weeks
5g USD 3650 2 Weeks
Bulk inquiry

Related CAS #: 753498-25-8 (malate)   312753-06-3 (free base)    

Synonym: QAB-149; QAB 149; QAB149; Indacaterol maleate; trade name Onbrez Breezhale; arcapta neohaler; Onbrez.

IUPAC/Chemical Name: (R)-5-(2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one maleate

InChi Key: IREJFXIHXRZFER-PCBAQXHCSA-N

InChi Code: InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1

SMILES Code: CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C(=C\C(=O)O)\C(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research.
In vitro activity: As shown in Fig. 2A, TNF-α induced the phosphorylation of IκBα and IKKα/β (the upstream activators of NF-κB), but indacaterol pretreatments (both 5 and 10 μM) under the same conditions suppressed their phosphorylation. Moreover, consistent with this result, TNF-α-induced NF-κB nuclear translocation was also largely inhibited by pretreatments with 5 and 10 μM indacaterol (Fig. 2B). Therefore, these results suggest that indacaterol may inhibit NF-κB-dependent target gene expression by reducing the activity of NF-κB upstream activators. Reference: Mol Cells. 2014 Aug;37(8):585-91. https://pubmed.ncbi.nlm.nih.gov/25134539/
In vivo activity: Treatment with either metoprolol or indacaterol alone significantly reduced the infarct size (8.50 ± 0.87% and 12.50 ± 1.44%, respectively; P < 0.001) with respect to untreated animals. Metoprolol or indacaterol alone or in combination significantly reduced cardiac GRK2 expression after 15 weeks in the failing rat hearts (Figure 2D, E). Reference: Br J Pharmacol. 2015 Jul;172(14):3627-37. https://pubmed.ncbi.nlm.nih.gov/25825265/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 101.0 198.60

Preparing Stock Solutions

The following data is based on the product molecular weight 508.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Lee SU, Ahn KS, Sung MH, Park JW, Ryu HW, Lee HJ, Hong ST, Oh SR. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37(8):585-91. doi: 10.14348/molcells.2014.0076. Epub 2014 Aug 18. PMID: 25134539; PMCID: PMC4145369. 2. Scola AM, Loxham M, Charlton SJ, Peachell PT. The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol. 2009 Sep;158(1):267-76. doi: 10.1111/j.1476-5381.2009.00178.x. Epub 2009 Apr 9. PMID: 19371332; PMCID: PMC2795262. 3. Rinaldi B, Donniacuo M, Sodano L, Gritti G, Martuscelli E, Orlandi A, Rafaniello C, Rossi F, Calzetta L, Capuano A, Matera MG. Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015 Jul;172(14):3627-37. doi: 10.1111/bph.13148. Epub 2015 May 12. PMID: 25825265; PMCID: PMC4507164.
In vitro protocol: 1. Lee SU, Ahn KS, Sung MH, Park JW, Ryu HW, Lee HJ, Hong ST, Oh SR. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37(8):585-91. doi: 10.14348/molcells.2014.0076. Epub 2014 Aug 18. PMID: 25134539; PMCID: PMC4145369. 2. Scola AM, Loxham M, Charlton SJ, Peachell PT. The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol. 2009 Sep;158(1):267-76. doi: 10.1111/j.1476-5381.2009.00178.x. Epub 2009 Apr 9. PMID: 19371332; PMCID: PMC2795262.
In vivo protocol: 1. Rinaldi B, Donniacuo M, Sodano L, Gritti G, Martuscelli E, Orlandi A, Rafaniello C, Rossi F, Calzetta L, Capuano A, Matera MG. Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015 Jul;172(14):3627-37. doi: 10.1111/bph.13148. Epub 2015 May 12. PMID: 25825265; PMCID: PMC4507164.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Rossi A, Zanardi E, Poletti V, Cazzola M. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. Int J Chron Obstruct Pulmon Dis. 2015 Jul 23;10:1383-92. doi: 10.2147/COPD.S55488. eCollection 2015. Review. PubMed PMID: 26229457; PubMed Central PMCID: PMC4516211.

2: Horita N, Kaneko T. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2015 Apr 21;10:813-22. doi: 10.2147/COPD.S56067. eCollection 2015. Review. PubMed PMID: 25960646; PubMed Central PMCID: PMC4410821.

3: Matera MG, Rogliani P, Cazzola M. QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 May;16(7):1079-90. doi: 10.1517/14656566.2015.1032247. Epub 2015 Apr 5. Review. PubMed PMID: 25843089.

4: Pelaia G, Maselli R, Gallelli L. Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium. Multidiscip Respir Med. 2014 Dec 8;9(1):64. doi: 10.1186/2049-6958-9-64. eCollection 2014. Review. PubMed PMID: 25699181; PubMed Central PMCID: PMC4333835.

5: Ridolo E, Montagni M, Riario-Sforza GG, Baroni M, Incorvaia C. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. Ther Adv Respir Dis. 2015 Apr;9(2):49-55. doi: 10.1177/1753465815572065. Epub 2015 Feb 17. Review. PubMed PMID: 25691493.

6: Prakash A, Babu KS, Morjaria JB. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2015 Jan 7;10:111-23. doi: 10.2147/COPD.S67758. eCollection 2015. Review. PubMed PMID: 25609944; PubMed Central PMCID: PMC4293295.

7: Pelaia G, Maselli R, Matera MG. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium. Pharmacology. 2014;94(5-6):249-58. doi: 10.1159/000368986. Epub 2014 Nov 28. Review. PubMed PMID: 25471458.

8: Murphy L, Rennard S, Donohue J, Molimard M, Dahl R, Beeh KM, Dederichs J, Fülle HJ, Higgins M, Young D. Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs. 2014 Sep;74(14):1635-57. doi: 10.1007/s40265-014-0284-7. Review. PubMed PMID: 25212789.

9: Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. Int J Chron Obstruct Pulmon Dis. 2014 Jul 31;9:813-24. doi: 10.2147/COPD.S59673. eCollection 2014. Review. PubMed PMID: 25114521; PubMed Central PMCID: PMC4124050.

10: Ulrik CS. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstruct Pulmon Dis. 2014 Apr 1;9:331-8. doi: 10.2147/COPD.S60362. eCollection 2014. Review. PubMed PMID: 24729699; PubMed Central PMCID: PMC3979690.

11: Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014 Mar;74(4):465-88. doi: 10.1007/s40265-014-0194-8. Review. PubMed PMID: 24604791.

12: Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Chest. 2014 Aug;146(2):309-17. doi: 10.1378/chest.13-2807. Review. PubMed PMID: 24556877.

13: Seth HD, Sultan S, Gotfried MH. Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease. J Thorac Dis. 2013 Dec;5(6):806-14. doi: 10.3978/j.issn.2072-1439.2013.10.11. Review. PubMed PMID: 24409359; PubMed Central PMCID: PMC3886694.

14: Steiropoulos P, Archontogeorgis K, Nena E, Bouros D. New developments in the management of COPD: clinical utility of indacaterol 75 μg. Int J Chron Obstruct Pulmon Dis. 2014;9:1-7. doi: 10.2147/COPD.S24940. Epub 2013 Dec 6. Review. PubMed PMID: 24353414; PubMed Central PMCID: PMC3862584.

15: Cazzola M, Calzetta L, Page CP, Matera MG. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):129-37. doi: 10.1517/17425255.2014.865723. Epub 2013 Dec 3. Review. PubMed PMID: 24295085.

16: Ridolo E, Montagni M, Olivieri E, Riario-Sforza GG, Incorvaia C. Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:425-32. doi: 10.2147/COPD.S49179. Epub 2013 Sep 18. Review. PubMed PMID: 24082783; PubMed Central PMCID: PMC3785397.

17: Chung VC, Ma PH, Hui DS, Tam WW, Tang JL. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One. 2013 Aug 14;8(8):e70784. doi: 10.1371/journal.pone.0070784. eCollection 2013. Review. PubMed PMID: 23967106; PubMed Central PMCID: PMC3743831.

18: Rossi A, Polese G. Indacaterol: a comprehensive review. Int J Chron Obstruct Pulmon Dis. 2013;8:353-63. doi: 10.2147/COPD.S21625. Epub 2013 Jul 25. Review. PubMed PMID: 23922496; PubMed Central PMCID: PMC3728154.

19: Schachter EN. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc). 2013 Jul;49(7):437-46. doi: 10.1358/dot.2013.49.7.1980496. Review. PubMed PMID: 23914352.

20: Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med. 2013 Apr 25;13:26. doi: 10.1186/1471-2466-13-26. Review. PubMed PMID: 23617268; PubMed Central PMCID: PMC3651265.